A selected list of oncolytic viruses in clinical trials
Click on the company or institution name for more information on the clinical trials
| Virus | Selective targeting method | Indications | Human trial status | Companies/Institutions (candidate) |
| Adenovirus | E1B deletion restricts replication to cells with abberant mRNA transport | Head and neck tumors | Phase III | Sunway Biotech of China (H101) |
| Head and neck tumors | Phase III (canceled) | Onyx (O15) | ||
| Coxsackie virus | Targets DAF/intercellular adhesion molecule 1, which is overexpressed in cancer | Stage IV melanoma | Phase I | Viralytics (A21) |
| Herpes simplex virus 1 | ICP34.5 deletion restricts replication to cells with active replication | Melanoma | Phase II | BioVex (OncoVEXGM-CSF) |
| Glioma, astrocytoma, glioblastoma | Phase I/II | MediGene (G207, NV1020) | ||
| Glioma, melanoma, squamous cell carcinoma of the head and neck | Phase I/II | Crusade Laboratories (HSV1716) | ||
| Measles virus | Engineered to target CD46 on tumor cells | Brain and central nervous system tumors | Phase I | Mayo Clinic (MV-CEA) |
| Newcastle disease virus | Naturally unable to... |
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
